We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma.
- Authors
Chen, Qiuying; Zhang, Bin; Dong, Yuhao; Mo, Xiaokai; Zhang, Lu; Xia, Jiejun; Zhang, Jing; Zhang, Shuixing
- Abstract
<bold>Purpose: </bold>Although intra-arterial chemotherapy (IAC) is commonly used for treating intraocular retinoblastoma, it is not a systemic therapy. We aimed to investigate whether the addition of intravenous chemotherapy (IVC) before IAC administration had any effects (whether beneficial or adverse) on patient outcomes.<bold>Methods: </bold>This multicenter retrospective cohort study included 213 patients with advanced intraocular retinoblastoma who received IVC plus IAC (n = 103) or IAC alone (n = 110) between April 2009 and January 2017. Eyes were grouped according to the International Intraocular Retinoblastoma Classification. Kaplan-Meier and Cox regression analyses were performed to compare survival outcomes between the two groups. Moreover, details regarding enucleation were recorded.<bold>Results: </bold>The 3-year ocular survival rates were 62% in the IVC plus IAC group and 68% in the IAC group (hazard ratio (HR) 0.88, 95% confidence interval (CI) 0.55-1.43, P = 0.61). Moreover, the corresponding 3-year overall survival rates were 97% and 93%, respectively (HR 1.56, 95% CI 0.41-5.90, P = 0.51), while the 3-year event-free survival rates were 76% and 72%, respectively (HR 0.96, 95% CI 0.56-1.65, P = 0.89).<bold>Conclusions: </bold>Within a 3-year follow-up period, IVC plus IAC produced no additional benefit over primary IAC for treating advanced intraocular retinoblastoma in terms of local tumor control and extending survival. Longer follow-up periods are required to assess long-term efficacy.
- Subjects
CANCER chemotherapy; RETINOBLASTOMA; REGRESSION analysis; SURGICAL enucleation; CONFIDENCE intervals
- Publication
Cancer Chemotherapy & Pharmacology, 2020, Vol 85, Issue 4, p723
- ISSN
0344-5704
- Publication type
journal article
- DOI
10.1007/s00280-020-04036-w